Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 173   

Articles published

PFE 34.59 -0.07 (-0.20%)
price chart
Pfizer, Novartis say meningitis vaccine scope too narrow
(Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory committee on Thursday recommended meningitis B vaccines for people at high risk aged 10 to 25, a population that Pfizer Inc and Novartis criticized as too narrow. Pfizer's ...
NICE Okays Pfizer Inc. Inlyta, Rejects Dendreon Corporation Provenge; Bad ...
The National Institute for Health and Care Excellence (NICE) issued two final guidelines today, recommending Pfizer Inc.'s (NYSE:PFE) Inlyta (axitinib) to be used as a second-line treatment option for kidney cancer, while rejecting Dendreon Corporation ...
Has Pfizer Inc. Finally Solved Its Immuno-oncology Problem?
In the company's most recent conference call, management shed some additional light on the duo's plans for clinical development.
Pfizer to cut jobs at Cambridge research center
Drug giant Pfizer Inc. said Tuesday that it plans to pare an unspecified number of jobs at its Cambridge research center, opened last June, as part a broader cutback across its research operations.
Pfizer Australia Lipitor Case Dismissed
MELBOURNE, Australia--The Federal Court of Australia on Wednesday dismissed a case against the local arm of Pfizer Inc. that alleged the drug company misused its market power to sell a popular cholesterol-lowering product.
Will Pfizer Inc. Break Up in 2015?
Pfizer has been churning out major new products such as its pneumonia and meningitis vaccine, Prevnar-13, during this time period.
Pfizer Inc. Is Not Done With Acquisition Deals Yet  Bidness ETC
Pfizer to pay $17 billion for Hospira Inc.  Allentown Morning Call
Pfizer Inc. (PFE) Closes 0.2% Down on the Day for February 26
Dow Jones component Pfizer Inc. ($PFE) saw its stock move -0.2% to $34.59, representing a per-share move of $0.07, on volume of 19.53 million shares for Thursday.
Will Pfizer Inc. Look to Buy Valeant Pharmaceuticals Intl Inc.?
There's no denying that the 2014 was the year of the acquisition in the pharmaceutical business. Big companies bought small companies; big companies bought even bigger companies.
Which Biotech Stock Should Pfizer, Inc. Buy?
Earlier this week, Pfizer announced that it would acquire Hospira, the top provider of injectable drugs. The deal will net Pfizer an intriguing biosimilar program, but some suspect that the company is still hungry for more. If Pfizer is indeed still on ...
Pfizer Becomes #4 Most Shorted Dow Stock, Replacing DuPont
In our new rank based on the most recent short interest data from NASDAQ, Pfizer Inc (NYSE: PFE) has taken over the position of #4 most shorted Dow component, from DuPont (NYSE: DD) which is now in the #12 spot.